Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.
Boumelha J, de Carné Trécesson S, Law EK, Romero-Clavijo P, Coelho MA, Ng KW, Mugarza E, Moore C, Rana S, Caswell DR, Murillo M, Hancock DC, Argyris PP, Brown WL, Durfee C, Larson LK, Vogel RI, Suárez-Bonnet A, Priestnall SL, East P, Ross SJ, Kassiotis G, Molina-Arcas M, Swanton C, Harris R, Downward J. Boumelha J, et al. Among authors: mugarza e. Cancer Res. 2022 Oct 4;82(19):3435-3448. doi: 10.1158/0008-5472.CAN-22-0325. Cancer Res. 2022. PMID: 35930804 Free PMC article.
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.
van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Kelly G, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J. van Maldegem F, et al. Among authors: mugarza e. Nat Commun. 2021 Oct 8;12(1):5906. doi: 10.1038/s41467-021-26214-x. Nat Commun. 2021. PMID: 34625563 Free PMC article.
CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer.
Boumelha J, de Castro A, Bah N, Cha H, de Carné Trécesson S, Rana S, Tomaschko M, Anastasiou P, Mugarza E, Moore C, Goldstone R, East P, Litchfield K, Lee SH, Molina-Arcas M, Downward J. Boumelha J, et al. Among authors: mugarza e. Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2627. Online ahead of print. Cancer Res. 2024. PMID: 38635884
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes.
Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, Abril-Rodriguez G, Berger-Manerio D, Pant A, Hu J, Gupta R, Vega-Crespo A, Baselga-Carretero I, Chen JM, Shin DS, Scumpia P, Radu RA, Chen Y, Ribas A, Puig-Saus C. Jilani S, et al. Among authors: mugarza e. Nat Commun. 2024 Feb 9;15(1):1244. doi: 10.1038/s41467-024-45221-2. Nat Commun. 2024. PMID: 38336975 Free PMC article.
GLP-1 nanomedicine alleviates gut inflammation.
Anbazhagan AN, Thaqi M, Priyamvada S, Jayawardena D, Kumar A, Gujral T, Chatterjee I, Mugarza E, Saksena S, Onyuksel H, Dudeja PK. Anbazhagan AN, et al. Among authors: mugarza e. Nanomedicine. 2017 Feb;13(2):659-665. doi: 10.1016/j.nano.2016.08.004. Epub 2016 Aug 20. Nanomedicine. 2017. PMID: 27553076 Free PMC article.